Skip to main content

Table 1 Potential use of EV-DNA as a biomarker for cancer

From: DNA in extracellular vesicles: from evolution to its current application in health and disease

Disease EVs source Isolation method EVs/DNA types Mutation References
Cancer
 Melanoma Cell lines preclinical mice model UC exo/dsDNA EGFR and BRAF [9]
 Pancreatic cancer Plasma UC exo/dsDNA KRAS, p53 [8]
 Pancreatic cancer Plasma UC exo/dsDNA KRAS, p53 [90, 91]
 Pancreatic cancer Plasma Microfluidic platform ev*/DNA* KRAS [92]
 Pancreatic cancer Serum UC exo/DNA* KRAS [93]
 Pancreatic cancer Seum and plasma ExoEasy Maxi Kit UC exo/DNA* KRAS [94]
 Glioma Small cohort UC ev*/DNA* Multiple mutations [95]
 Glioblastoma multiforme Cell lines PEG-NaCl precipitation exo/DNA* NANOGP8 a [96]
 Osteosarcoma Serum PEG precipitation SEC ev*/DNA* Repetitive element DNAs [38]
 Acute myeloid leukemia Plasma UC ev*/dsDNA   [97]
 Urothelial bladder carcinoma Clinical study/urine ExoQuick-TC c exo/DNA* Multiple mutations and CNVs b [98]
 Non-small cell lung cancer Plasma and bronchoalveolar lavage fluid UC ev*/DNA* EGFR [99]
 Lung adenocarcinoma Malignant pleural effusions ExoQuick-TC ExoLution plus isolation kit exo/dsDNA EGFR [100, 101]
 Pheochromocytomas and paragangliomas Serum preclinic UC exo/dsDNA Multiple [102]
 Ovarian cancer Plasma miRCURY ™ kit c Exo/mtDNA Copy number of mtDNA [103]
Other conditions
 Tuberculosis Clinical specimens ExoQuick™ exo/DNA* MTB-specific IS6110 [104]
 Fetal trisomy Plasma ExoQuick™ ev*/DNA* Trisomies, and de novo FGFR3 mutations [105]
  1. *Not identified
  2. aAn insertion of 22 bp of NANOGP8 gene into the 3′ UTR
  3. bCopy number variation (CNV)
  4. cCommercial exosome precipitation kit